IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More
Researchers from the University of Birmingham are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future anti-viral drugs. The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor,… Read More
The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies. LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its… Read More
Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of… Read More
Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise or stop infection from variants that are circulating in South Africa, Brazil and elsewhere. The data suggests that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly,… Read More
eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases, has announced the award of a TIGER grant of €6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of… Read More
The Russian Direct Investment Fund (RDIF) and Stelis Biopharma, the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against COVID-19, sufficient to vaccinate 100 million people. Sputnik V is now approved for… Read More
Biotechnology company PerkinElmer has announced its documentation, workflow and decision-making informatics platform, Signals, is expanding to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community. With the collaboration, pharmaceutical and academic research… Read More
The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More
NanoTemper Technologies will be running a case study and walk through of Prometheus Panta. Join the company on 30 March to learn how to make formulation workflow more efficient with multi-parameter stability characterisation. This event will provide new perspectives on data and will look at how running thermal unfolding, particle… Read More
Andrew Aldridge, Partner at Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and… Read More
LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC), have announced three major investments totalling £18 million to create a network of gene therapy innovation hubs. The funding will support the creation of three facilities to advance the clinical development of… Read More
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have begun Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. Medicago received approval from Canadian and U.S. regulatory authorities to proceed with enrolment… Read More
Axol Bioscience, provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, have signed a merger agreement. The new entity will become a provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modelling for… Read More
Bio-Techne, a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities, announced that its Bristol site has received ISO 9001:2015 Quality Management Systems certification. Bio-Techne’s Bristol facility produces life science reagents for research use. ISO 9001:2015 is an internationally recognised quality standard intended… Read More
